Want to see FR:GNFT full AI Analyst Report?
GNFT Stock Chart & Stats
€9.18
-€0.03(-0.72%)
At close: 4:00 PM EST
€9.18
-€0.03(-0.72%)
Day’s Range― - ―
52-Week Range€3.05 - €12.98
Previous CloseN/A
Volume32.76K
Average Volume (3M)245.75K
Market Cap
€527.89M
Enterprise Value€550.39M
Total Cash (Recent Filing)€101.09M
Total Debt (Recent Filing)€150.69M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Sep 29, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding50,096,220
10 Day Avg. Volume239,968
30 Day Avg. Volume245,745
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.00Price Target Upside63.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.12
Revenue Forecast (FY)€87.89M
Bulls Say, Bears Say
Bulls Say
Specialized Product FocusA clear, specialized focus on metabolic and liver diseases with proprietary diagnostic and therapeutic technology supports a durable competitive position. Niche expertise improves barrier to entry, strengthens regulatory and clinical know-how, and helps attract targeted partnerships and recurring diagnostic revenue over time.
Meaningful 2025 Revenue ReboundA strong top-line rebound indicates renewed commercial traction and market demand, suggesting the business model can scale when execution aligns. Sustained revenue growth over multiple quarters would support investment in R&D and commercialization and reduce dependence on one-off funding sources.
Proven Cash Generation In Select YearsHistorical ability to generate positive operating and free cash flow in certain years demonstrates the company can convert commercial activity into cash. This track record implies that, if management restores consistent execution and margins, the firm has a pathway to self-funded operations without permanent reliance on dilutive financing.
Bears Say
Negative Shareholders' EquityNegative shareholders' equity is a structural red flag indicating capital erosion and reduced loss-absorption capacity. It constrains financing options, raises covenant and refinancing risks, and increases the probability of dilution or distressed funding if operating losses persist, undermining long-term stability.
Renewed Cash Burn In 2025A return to negative operating and free cash flow signals renewed cash burn and reliance on external funding. Inconsistent cash generation complicates multi-year R&D and commercialization planning, heightens financing risk, and may force unfavorable partner deals or dilution, weakening strategic flexibility.
Highly Volatile ProfitabilityPronounced swings between profit and large losses reflect execution and margin volatility. This undermines predictability for investors, partners, and lenders, complicates long-term budgeting, and raises questions about sustainable unit economics and the durability of recent revenue gains absent steady margin improvement.
Genfit News
GNFT FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was €3.05 and its highest was €12.98 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is €527.89M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Sep 29, 2026 which is in 86 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Apr 02, 2026. The company reported -€1.525 earnings per share for the quarter, missing the consensus estimate of -€0.03 by -€1.495.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.02.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,096,220 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -€1.525 in its last earnings report, missing expectations of -€0.03. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in FR:GNFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
GNFT Stock 12 Month Forecast
Average Price Target
€15.00
▲(63.40% Upside)
Technical Analysis
Options Prices
Currently, No data available
---